linjc16/ctgov huggingface dataset:
Study of the Role of Innate Lymphoid Cells and Natural Killer Cells in Immune Activation of Vitiligo - INNATE Vitiligo

Study Overview
=================
Brief Summary
-----------------
The cohort included only major patients with non-segmental vitiligo and no other autoimmune or inflammatory associated diseases (except thyroiditis). Control subjects should have no autoimmune or inflammatory diseases. Patients and controls should not take treatment with corticosteroids or other potentially immunomodulatory therapies. Patients and controls are recruited in the Dermatology Department of the University Hospital of Nice and the Hospital of Fréjus. The investigators have already initiated the collection of tissues and blood from patients and control subjects and we have succeeded in isolating ILCs and NKs from a blood volume of 50ml. We were able to sort the ILC subpopulations. Early data suggest an increase in Natural Killer (NK) and Innate Lymphoïdes Cells 1 (ILC1) in the blood of vitiligo patients compared to control subjects. The investigators also managed to extract the melanocytes from the skin biopsies of the first patients and control subjects.

Detailed Description
-----------------
The investigators want study the presence and type of ILC and NK in the blood and skin of vitiligo patients compared to control subjects.

Official Title
-----------------
Study of the Role of Innate Lymphoid Cells and Natural Killer Cells in Immune Activation of Vitiligo

Conditions
-----------------
Vitiligo

Intervention / Treatment
-----------------
* Other: blood and skin samples


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: vitiligo subjects : patients in the cohort with non-segmental vitiligo without other autoimmune or inflammatory diseases associated control subjects : subject without autoimmune or inflammatory disease

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| patients with Vitiligo<br> | Other: blood and skin samples<br>* To study the presence and type of ILC and NK in the blood and skin of vitiligo patients compared to control subjects.<br>|
| control<br> | Other: blood and skin samples<br>* To study the presence and type of ILC and NK in the blood and skin of vitiligo patients compared to control subjects.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| study the presence and type of ILC and NK in the blood and skin | Compare vitiligo patients to control subjects. | 1 day | 
| study the presence and type of ILC and NK in the skin | Compare vitiligo patients to control subjects. | 1 day |
Virtual Colonoscopy (VC) for Primary Colorectal Screening

Study Overview
=================
Brief Summary
-----------------
This study involves a primary VC screening for colorectal polyps. The research hypothesis is that VC screening, including surveillance of sub-cm polyps, is a safe and effective approach.

Detailed Description
-----------------
The purpose of this study is to use virtual colonoscopy screening to learn more about what happens to small colon polyps (less than 10 mm) over time. From this, we can find out whether it's safer to remove all colon polyps right away or leave the small ones in place and remove only those that grow to 10 mm or more.

Official Title
-----------------
CT Virtual Colonoscopy for Primary Colorectal Screening

Conditions
-----------------
Colorectal Polyps

Intervention / Treatment
-----------------
* Other: CTC surveillance


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Medium-sized colorectal polyps (6-9 mm) Exclusion Criteria: No medium-sized colorectal polyps (6-9 mm)

Ages Eligible for Study
-----------------
Minimum Age: 50 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| A<br>In vivo surveillance of 6-9 mm polyps detected at CTC | Other: CTC surveillance<br>* In vivo CTC surveillance of 6-9 mm polyp<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The growth rate (natural history) of small colorectal polyps | Polyp growth rates are established by comparing polyp volume at the initial and surveillance CTC studies | The outcome measure of polyp growth rate is established at the time of surveillance CTC by comparing to the baseline CTC | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
colorectal, polyps
Long Time Follow up After HJ Following Iatrogenic Bile Duct Injuries

Study Overview
=================
Brief Summary
-----------------
Introduction: Bile duct injury (BDI) after cholecystectomy remains a serious complication with major implications for patient outcome. For most major BDIs, the recommended method of repair is a hepaticojejunostomy (HJ). We conducted a retrospective review from 5 Danish hepatobiliary centres aiming to examine the perioperative and the long-term outcome after reconstructive HJ.

Official Title
-----------------
Langtidsopfølgning Efter Kirurgisk Behandling af Iatrogene galdevejslæsioner opstået i Forbindelse Med Cholecystektomi

Conditions
-----------------
Biliary Strictur After Hepatojejunostomy (HJ), Morbidity and Mortality After and Around HJ

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All patients with iatrogenic Bile duct injury (BDI) after cholecystectomy reconstructed with hepatojejunostomy/choledochojejunostomy. Exclusion Criteria: Patients with non-cholecystectomy-related BDI or with cholecystectomy-related BDI that had been definitively managed by other techniques.
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Stricture of HJ | Stricture of hepaticojejunostomy after reconstruction | days to years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Biliary strictur, Hepatojejunostomy, Iatrogenic major bile duct injury
Computer Guided Buccal Cortical Plate Separation for Removal of Calcified Benign Odontogenic Tumors Affecting Mandibular Angle Region

Study Overview
=================
Brief Summary
-----------------
Computer guided buccal cortical plate separation was performed for ten patients using patient specific osteotomy locating guides and pre-bent plates. The guide was designed to outline the osteotomy, buccal cortical plate was separated, the lesion was removed, finally the pre-bent plates were used to fix the separated cortex.

Detailed Description
-----------------
Computer guided buccal cortical plate separation was performed for ten patients using patient specific osteotomy locating guides and pre-bent plates. The guide was designed to outline the osteotomy, buccal cortical plate was separated, the lesion was removed, finally the pre-bent plates were used to fix the separated cortex.

Official Title
-----------------
Computer Guided Buccal Cortical Plate Separation for Removal of Calcified Benign Odontogenic Tumors Affecting Mandibular Angle Region

Conditions
-----------------
Odontogenic Tumors, Odontoma

Intervention / Treatment
-----------------
* Other: Computer guided buccal cortical plate separation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with well-defined radiopaque lesion affecting angle region, its conventional removal may compromise the bone continuity and leads to pathological fracture indicating the need of buccal cortical plate separation technique Exclusion Criteria: Patients with any medical condition contraindicating the surgical procedures were excluded
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Computer guided buccal cortical plate separation<br>Computer guided buccal cortical plate separation for removal of calcified benign odontogenic tumors | Other: Computer guided buccal cortical plate separation<br>* Computer guided buccal cortical plate separation for removal of calcified benign odontogenic tumors<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Intra-operative time | Intra-operative time was measured from the start of the incision till suturing | during the surgery | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Postoperative pain | Postoperative pain using 0 - 10 visual analog scale | 2, 5, and 10 days after the surgery | 
| Edema | Edema was assessed using a four grades scale: Grade 0, No edema; Grade 1, mild edema (just visible); Grade 2; moderate edema (local); Grade 3, severe edema (extended). | 5 and 10 days after the surgery |
The Effectiveness and Safety of Vagus Nerve Stimulation for TRE

Study Overview
=================
Brief Summary
-----------------
Prospective controlled studies to identify clinical epilepsy control, cognitive changes, and safety in VNS treatment of tuberculosis-related epilepsy.

Detailed Description
-----------------
Control group: no clear epilepsy focus in the brain, and medication has been continued. Surgery group: no clear epilepsy focus in the brain, and VNS for tuberculosis-related epilepsy. In order to ensure the follow-up of the study and 3 years after the end of the study, 50 cases were collected in each group of the study.

Official Title
-----------------
Clinical Evaluation of the Effectiveness and Safety of Vagus Nerve Stimulation for Tuberous Sclerosis Complex Related Epilepsy

Conditions
-----------------
Tuberous Sclerosis Complex, Epilepsy

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 2 years old and above, no gender restriction, TSC gene monitoring with or without abnormality Diagnosis of nodular sclerosis and epilepsy Epilepsy course for more than 1 year Patients who have taken 3 or more reasonable choices with appropriate and tolerable antiepileptic drugs (excluding mTOR inhibitors and traditional Chinese medicine and prescriptions) had seizures more than 12 times in the 3 months before enrollment The family members agreed to enroll and signed the informed consent. Exclusion Criteria： Obvious renal angiomyolipoma, pulmonary lymphoma leiomyomatosis, and subventricular giant cell astrocytoma Abnormal heart, lung, liver, and kidney functions and coagulation function The family did not sign the informed consent Preoperative evaluation, it is considered that no surgical treatment is needed The patient received other craniocerebral surgical treatment within 1 year during the follow-up period

Ages Eligible for Study
-----------------
Minimum Age: 2 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| % of patients with ILAE grading | The grading made by ILAE for the classification of outcome with respect to epileptic seizures following epilepsy surgery. It contains a total of 6 levels. The higher the level, the worse the result. We will count the percentage of patients at each level.epileptic seizures following epilepsy surgery. It is used for assessing the control of epilepsy. | 3 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| IQ | Wechsler Intelligence Scale is used for the evaluation of IQ | 3 years | 
| Quality of Life: QOLIE-31 | QOLIE-31 is suitable for patients 14 years and older. QOLCE-76 is applied to patients aged 2-13 by parents. | 3 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
tuberous sclerosis complex, epilepsy, vagus nerve stimulation
A Dose Ranging Study to Compare the Safety and Efficacy of Aliskiren 150mg, 300mg, and 600mg to Placebo in Patients With High Blood Pressure.

Study Overview
=================
Brief Summary
-----------------
Evaluate the blood pressure lowering effect of aliskiren 150mg, 300mg and 600mg compared to placebo in patients with essential hypertension

Official Title
-----------------
An Eight-week, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study Comparing Aliskiren 150 mg, 300 mg, and 600 mg to Placebo in Patients With Essential Hypertension

Conditions
-----------------
Hypertension

Intervention / Treatment
-----------------
* Drug: aliskiren


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria Patients with essential hypertension Patients who are eligible and able to participate in the study Exclusion Criteria Severe hypertension History or evidence of a secondary form of hypertension History of Hypertensive encephalopathy or cerebrovascular accident. Other protocol-defined exclusion criteria may apply.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: aliskiren|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change from baseline in diastolic blood pressure after 8 weeks |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change from baseline in systolic blood pressure after 8 weeks |  |  | 
| Diastolic blood pressure < 90 mmHg or a reduction of > 10 mmHg after 4 weeks and 8 weeks |  |  | 
| Blood pressure <140/90 mmHg after 4 weeks and 8 weeks |  |  | 
| Evaluate potential return of hypertension at 4 days and 2 weeks after 8 weeks |  |  | 
| Evaluate high and low level drug effect using 24 hour blood pressure monitoring |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Hypertension, aliskiren, blood pressure, placebo
Prevalence of Heterozygote Mothers for Pompe's Disease Among Mothers Having Delivered in French Guiana

Study Overview
=================
Brief Summary
-----------------
Given the high incidence of Pompe's Disease in French Guiana (100 times higher than in mainland France) the aim is to determine the prevalence of heterozygotes among women having just delivered in French Guiana who accepted that their newborn child enters the depipomp1 study. In these women the specific mutations p.Gly648Ser and p.Arg854X will be sought using PCR in order to calculate the prevalence of these mutations and estimate the risk factors associated with them in order to improve genetic counselling.

Official Title
-----------------
Prevalence of Heterozygote Mothers for Pompe's Disease Among Mothers Having Delivered in French Guiana

Conditions
-----------------
Pompe's Disease

Intervention / Treatment
-----------------
* Other: observational


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: women having delivered in French Guiana whose child was enroled in the depipomp1 study Exclusion Criteria: refusal to participate
Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: observational|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| prevalence of p.Gly648Ser and p.Arg854X | number of positive mutations divided by total number of women tested | Within 3 days after birth |
Effect of Theophylline in Pseudohypoparathyroidism

Study Overview
=================
Brief Summary
-----------------
The study evaluates the effect of theophylline in 100 subjects with Pseudohypoparathyroidism.

Detailed Description
-----------------
It is an open label intervention study for the off-label use of theophylline in psuedohypoparathyroidism (PHP).Theophylline is a is non-specific phosphodiesterase inhibitor which increases the levels of secondary messenger,cAMP. PHP patients have end organ resistance to hormones involving cAMP signaling. Thus, theophylline has a potential to abrogate hormone resistance. Also, it may have a role in bone maturation, neurocognition and metabolism.

Official Title
-----------------
Effect of Theophylline in Pseudohypoparathyroidism

Conditions
-----------------
PHP Ia, PHP IB, Php1C

Intervention / Treatment
-----------------
* Drug: Theophylline


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Subjects with known diagnosis of PHP1A and PHP1B Age >5 years Exclusion Criteria: • Significant kidney disease, i.e. any CKD stage Hypercalciuria Kidney stones Severe Heart disease Uncontrolled seizure disorder Peptic ulcer Liver dysfunction Bleeding disorder Allergy to theophylline preparation Muscle disorder Infection Any neurologic disease Chronic drugs interacting with theophylline

Ages Eligible for Study
-----------------
Minimum Age: 5 Years
Maximum Age: 21 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Intervention Model: Single Group Assignment
Interventional Model Description: Open label intervention study, off label use of theophylline
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Single arm open labeled intervention study<br>Subjects with PHP will be given theophylline to decrease the end organ resistance by increasing levels of cAMP, a second messenger. Theophylline will be dosed twice a day for a period of 52 weeks. | Drug: Theophylline<br>* Theophylline will be given to maintain a peak level between 10-15 mcg/mL<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Effect of Theophylline on Bone Age in PHP | Change in Bone age ( in years and months) before and after theophylline administration for 52 weeks | 52 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
PHP
The Neonatal Hemorrhagic Risk Assessment in Thrombocytopenia Study

Study Overview
=================
Brief Summary
-----------------
This is a prospective longitudinal study that evaluates Platelet Function Analyzer-100 (PFA-100) CT-ADPs (closure time-ADP) and incidence of bleeding using the Neonatal Bleeding Assessment Tool - Neo-BAT in preterm neonates <32 weeks gestational age or with a birth weight <1500 grams and with different degrees of thrombocytopenia. The investigators hypothesized that PFA-100 CT-ADP, a global in vitro test of primary hemostasis, will be a better predictor of clinical bleeding in neonates than platelet count alone. A bleeding risk assessment marker could help physicians more accurately determine the risk/benefit ratio of platelet transfusions, guiding platelet transfusion decisions in neonates with thrombocytopenia.

Official Title
-----------------
The Neonatal Hemorrhagic Risk Assessment in Thrombocytopenia Study - Neo-HAT Study

Conditions
-----------------
Thrombocytopenia

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: <32 weeks gestation or with a birth weight <1500 grams; Have confirmed moderate-to-severe thrombocytopenia, defined as a platelet count <100x109/L; Have a parent/guardian willing to comply with the protocol and provide written informed consent. Exclusion Criteria: Are not expected to survive by the Attending Neonatologist; Are thought to have a congenital thrombocytopenia or platelet dysfunction, based on family history or clinical presentation (e.g. associated congenital malformations, platelet morphology); Have a major chromosomal anomaly such as Trisomy 13, 18, or 21.
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Neo-BAT score (Neo-BAT: Neonatal Bleeding Assessment Tool) | The NeoBAT is a simple, reliable and objective tool for the standardized assessment of bleeding in neonates, which was developed by an international team of experts based on the World Health Organization bleeding score for adults. | study period: 5 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of thrombotic events |  | up to post-conceptional age 36 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Thrombocytopenia, Neonate, PFA-100, Neo-BAT, Hemorrhage